Biohaven Ltd. is advancing development of its first-in-class bispecific IgG degrader, BHV-1300, which has potential to treat multiple immune-mediated diseases. The pan-IgG degrader has demonstrated a competitive safety, manufacturable and pharmacodynamic profile, and BHV-1300 dosage regimens are expected to allow co-administration with existing standards of care. An IND submission is planned for the second half of this year.
Evaxion Biotech A/S has presented promising results on EVX-B1, a vaccine against Staphylococcus aureus containing antigens identified using artificial intelligence. EVX-B1 induces strong immune responses, both cellular and humoral, that translate to a high level of protection in preclinical models for skin infection and sepsis.
Indazole compounds acting as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors have been described in a recent Nippon Shinyaku Co. Ltd. patent as potentially useful for the treatment of irritable bowel syndrome, psoriasis, arthritis, bacterial infection, systemic lupus erythematosus, pancreatitis, asthma and chronic obstructive pulmonary disease, among others.
Avoidance of graft-vs.-host disease (GVHD) after a hematopoietic stem cell transplant could depend on certain members of the microbiome. According to a study led by scientists at the Fred Hutchinson Cancer Center (FHCC), while some species of intestinal bacteria repressed the expression of the major histocompatibility complex II (MHC-II), others induced it and triggered the immune response that produces GVHD.
Recludix Pharma Inc. has entered into a strategic collaboration with Sanofi SA to develop and commercialize first-in-class oral small-molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.
Since its emergence in late 2019, SARS-CoV-2 has killed nearly 7 million people. But at the same time, many infections, in particular in children and young adults, are asymptomatic with rapid viral clearance from the body. It remains unclear why many individuals are able to successfully clear infection without major complications while others develop severe disease, even without known risk factors for severe COVID-19 outcomes.
Now, a new study involving nearly 30,000 individuals has found that variation in the human leukocyte antigen (HLA) loci may underlie processes mediating asymptomatic infection. The findings were reported in the July 19, 2023, online edition of Nature.
Research led by Columbia University investigators has shed light on the immune pathway of the intestinal damage caused in celiac disease after gluten consumption. As reported in the July 14, 2023, issue of Science Immunology, the investigators showed an important role for cytotoxic T cells in addition to gluten-specific CD4+ T cells in the onset of celiac disease symptoms in a range of people with the condition.
A new study on the interleukin 1 (IL-1) pathway and its involvement in systemic inflammation and autoinflammatory diseases has described a mutation of the IL-1 receptor type 1 (IL-1R1) receptor associated with chronic recurrent multifocal osteomyelitis (CRMO). The variant p.Lys131Glu of this receptor was identified in a patient with CRMO. A peripheral blood mononuclear cell analysis showed an inflammatory event in lymphocytes, especially in monocytes and neutrophils. The research was conducted by a group of scientists at Zhejiang University in China and reported in the July 11, 2023, issue of Immunity.
After CAR T-cell immunotherapy for leukemia, some children have a longer remission because the engineered cells remain active and control or prevent the growth of new tumor cells. A new collaborative study has found that these persistent cells expressed certain genes that could be identified through a transcriptional signature. The finding could explain why the treatment does not work in some patients, and potentially help to improve it, reducing relapses.
RSS
